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Edited by Christian GriesingerAbstract The interaction of the P-b-Cat19–44 peptide, a 26 ami-
no acid peptide (K19AAVSHWQQQSYLDpSGIHpSGATT-
TAP44) that mimics the phosphorylated b-Catenin antigen, has
been studied with its monoclonal antibody BC-22, by transferred
nuclear Overhauser eﬀect NMR spectroscopy (TRNOESY) and
saturation transfer diﬀerence NMR (STD NMR) spectroscopy.
This antibody is speciﬁc to diphosphorylated b-Catenin and does
not react with the non-phosphorylated protein. Phosphorylation
of b-Catenin at sites Ser33 and Ser37 on the DSGXXS motif
is required for the interaction of b-Catenin with the ubiquitin li-
gase SCFb-TrCP. b-TrCP is involved in the ubiquitination and
proteasome targeting of the oncogenic protein b-Catenin, the
accumulation of which has been implicated in various human
cancers. The three-dimensional structure of the P-b-Cat19–44 in
the bound conformation was determined by TRNOESY NMR
experiments; the peptide adopts a compact structure in the pres-
ence of mAb with formation of turns around Trp25 and Gln26,
with a tight bend created by the DpS33GIHpS37 motif; the pep-
tide residues (D32-pS37) forming this bend are recognized by the
antibody as demonstrated by STD NMR experiments. STD
NMR studies provide evidence for the existence of a conforma-
tional epitope containing tandem repeats of phosphoserine mo-
tifs. The peptide’s epitope is predominantly located in the large
bend and in the N-terminal segment, implicating bidentate asso-
ciation. These ﬁndings are in excellent agreement with a recently
published NMR structure required for the interaction of b-Cate-
nin with the SCFb-TrCP protein.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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fragment1. Introduction
b-Catenin (b-Cat) is an oncogenic protein that plays an
important role in the Wnt signaling pathway [1,2] and is an
important component of the cadherin cell-adhesion complex
(Fig. 1). Wnt genes encode secreted signaling molecules that
play important roles in development and tumorigenesis [3,4].
Deregulation of Wnt signaling is responsible for several human
malignancies [5,6]. It is well known that serine-phosphoryl-
ation of b-Catenin by the Axin-glycogen synthase kinase
(GSK)-3b complex targets b-Catenin for degradation by the
ubiquitination–proteosome pathway [7–10], and mutations at
critical phosphoserine residues stabilize b-Catenin and cause
human cancers [11–13]. b-Catenin phosphorylation results in
its degradation when phosphorylated b-Catenin is speciﬁcally
recognized by b-transducin repeat-containing protein (b-
TrCP), an F-box/WD40-repeat protein that also associates
with Skp1, an essential component of the ubiquitination appa-
ratus [14].
It has been demonstrated that b-Catenin binds to the F-box
WD40 protein b-TrCP [15,16], the receptor component of the
multi subunit Skp1-Cullin-FBox (SCF)b-TrCPE3 ubiquitin
ligase complex through its phosphorylated serine residues at
positions 33 and 37 [17]. b-TrCP is also involved in the ubiqui-
tination and proteasome targeting of: (i) the HIV-1 protein Vpu
[17], which enhances the release of new virus particles from the
plasma membrane of cells infected with HIV-1 [18] whereas it
induces the degradation of the CD4 receptor in the endoplas-
mic reticulum; (ii) IjBa, the inhibitor of master transcription
factor NF-jB [16,19,20]; and (iii) ATF4, a member of the fam-
ily of transcription factors [21]. The antigenic peptides contain-
ing the DpSGXXpS motif constitute b-TrCP-associated
epitopes. The SCFb-TrCP complex speciﬁcally recognizes a 22-
residue b-Catenin polypeptide, a HIV-1 encoded virus protein
U (Vpu) peptide fragment of 22 amino acids, and a 19-amino
acid motif in IjBa in a phosphorylation-dependent mannerblished by Elsevier B.V. All rights reserved.
Fig. 1. (A) Schematic representation of the b-Catenin. (a) The three-dimensional structure of a protease-resistant fragment of b-Catenin containing
the armadillo repeat region. The core region of b-Catenin is composed of 12 copies of a 42 amino acid sequence motif known as an armadillo repeat.
The 12 repeats form a super helix of helices that features a long, positively charged groove of the proteolyse resistant fragment [52]. The structure of
the N and C terminal domains remain unresolved. (b) Primary structure sequence of the full b-Catenin protein. The 12 armadillo repeats are shown in
green. The phosphorylation site containing the consensus motif DpSGXXpS is shown in yellow. (c) The sequence of the phosphorylated b-Catenin
fragment, P-b-Cat19–44 which was investigated in the present work. (d) The a-cadherin/b-Catenin complex connects to the actin via a-Catenin and
some actin-binding proteins, forming a rigid cytoskeleton. b-Catenin is involved in the Wingless/Wnt signaling pathway. When cells are exposed to
Wnt signal, cell surface receptors are activated and block b-Catenin phosphorylation and its subsequent ubiquitination. b-Catenin is thus diverted
from the proteasome, and it accumulates and enters the nucleus, where it ﬁnds a partner of the TCF/LEF family. Together, they activate new gene
expression programs.
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by b-TrCP is the phosphorylation of the serine residues present
in a conserved motif, DpSGXXpS for b-Catenin, Vpu, IjBa
and DpSGXXXpS for ATF4. It was recently shown thatVpu is a competitive inhibitor of b-TrCP that impairs the deg-
radation of SCFb-TrCP substrates as long as Vpu has an intact
DpSGXXpS phosphorylation motif and can bind to b-TrCP
[22].
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human cancers have been developed [23]. A monoclonal anti-
body reacting speciﬁcally with b-Catenin phosphorylated at
serine Ser33 and Ser37 is an essential tool in deﬁning the inter-
actions, distribution, and regulation/deregulation of b-Catenin
and its role in signal transduction. A speciﬁc monoclonal anti-
body (mAb) was generated against the P-b-Cat32–45 peptide
(Fig. 1), DpSGIHpSGATTTAPS (numbers refer to the b-
Catenin protein). We postulate that structural similarities
can occur between the small peptide ligand and the same se-
quence found within the intact protein, so when anti-ligand
monoclonal antibodies recognizing the peptide were obtained,
they are very good tools for the evaluation of structural ele-
ments of the intact protein bound by the natural receptor (b-
TrCP). This antibody is speciﬁc to the native phosphorylated
b-Catenin containing the DpS33GIHpS37 amino acid sequence
in the central part, and does not react with the nonphosphor-
ylated protein. In addition, we showed previously that the P-b-
Cat19–44 phosphorylated peptide has structural features diﬀer-
ent from those of its parent b-Cat19–44 peptide [24].
Antibody recognizes the P-b-Cat32–45 peptide, a small anti-
gen-binding fragment, and a fragment generally retains the
speciﬁcity and aﬃnity of the entire parent protein. Antirecep-
tor antibodies have been successfully used for the investigation
of ligand–receptor interactions as the internal complementary
binding region of the receptor binding site [25,26]. This latter
approach can be especially useful when (a) isolation of the
receptor in a suitable form for structural studies of the recep-
tor–ligand interaction is extremely diﬃcult or (b) little infor-
mation is available for its active state [27]. Thus,
determination of the conformational features of the P-b-Cate-Table 1
1H NMR chemical shifts (ppm) of the free P-b-Cat19–44 peptide from TSP-d
Residue d NH d Ha d Hb
Ac
Lys 19 8.42 4.24 1.79
Ala 20 8.53 4.28 1.38
Ala 21 8.47 4.31 1.45
Val 22 8.27 4.12 2.04
Ser 23 8.52 4.42 3.78/3.73
His 24 8.59 4.63 3.08
Trp 25 8.16 4.56 3.25
Gln 26 8.14 4.11 1.94/1.78
Gln 27 8.26 4.12 2.04/1.98
Gln 28 8.53 4.28 2.01/1.96
Ser 29 8.44 4.42 3.79
Tyr 30 8.30 4.56 2.96/3.03
Leu 31 8.21 4.32 1.53
Asp 32 8.21 4.61 2.75
pSer 33 9.22 4.46 4.18/4.12
Gly 34 8.62 3.92
Ile 35 8.07 4.03 1.79
Hc2 0.82 0.82
His 36 8.80 4.81 3.15/3.32
pSer 37 9.37 4.47 4.11
Gly 38 8.78 4.01
Ala 39 8.28 4.42 1.44
Thr 40 8.45 4.45 4.27
Thr 41 8.38 4.46 4.26
Thr 42 8.35 4.33 4.17
Ala 43 8.57 4.61 1.38
Pro 44 – 4.39 2.32/1.96
NH2
aSpectra were recorded at 278 K and pH 7.2 in 20 mM sodium phosphate bnin DpSGXXpS moiety implicated in antibody binding should
provide complementary information about the structural
parameters characterizing b-Catenin-b-TrCP receptor interac-
tion [28] to improve the understanding of the substrate speci-
ﬁcity of SCFb-TrCP. The structural characterization of the
DpSGXXpS moiety may have an additional interest. This will
contribute to the design of molecules mimicking the structure
of the b-Catenin adhesion site and possibly thus acting as a
potent model for the DpSGXXpS-protein complex.
Here, we present the STD NMR epitope mapping and
TRNOE-based conformational analysis of the P-b-Cat19–44
peptide bound to the monoclonal antibody, mAb. The trans-
ferred nuclear Overhauser eﬀect spectroscopy (TRNOESY)
experiment has been used to determine the conformations of
a wide range of small ligands in the protein-bound state by
focusing on the easily detected NMR signals of the free ligands
[29]. The mAb-bound P-b-Cat19–44 peptide conformation was
ﬁnally elucidated by molecular dynamics simulation, an ap-
proach combining dynamical annealing and reﬁnement proto-
cols. Saturation transfer diﬀerence (STD) NMR [30–32] is a
technique that can be used to characterize and identify bind-
ing. It can also be used to identify the binding epitope of
ligands to a protein receptor [32].2. Results
2.1. Binding of mAb BC-22 to the phosphorylated P-b-Cat19–44
peptide
The monoclonal anti-diphospho-b-Catenin (pSer33 and
pSer37) reacts speciﬁcally with b-Catenin diphosphorylated4
a
d Hc d Hd d others
2.03
1.45 1.78 2.99
0.91/0.88
2H 8.11; 4H 7.01
NeH 10.25
2H 7.23; 4H 7.53; 5H 7.14; 6H 7.25; 7H 7.49
2.10 6.92/7.51
2.34 7.00/7.65
2.31 6.95/7.59
7.08 6.79
1.45 0.83/0.88
Hc1 1.15/1.44
2H 8.46; 4H 7.23
1.22
1.22
1.22
2.05 3.67/3.81
7.79/7.14
uﬀer and a 9:1 H2O/
2H2O mixture (by volume).
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binding to block the P-b-Cat19–44 peptide, which contained the
consensus sequence DpSGXXpS. At the peptide level, the
antibody recognizes eﬃciently the P-b-Cat19–44 peptide and
not the nonphosphorylated one [23]. Given the uncertainties
in the eﬀective concentration of mAb that was immobilized
on the ELISA plate, the KD for peptide P-b-Cat
19–44 bound
to mAb was estimated to be between 100 and 500 lM. This
range of binding aﬃnity made the peptide likely to be suitable
for TRNOESY NMR experiments, which require fast ex-
change between the free and bound states.
2.2. NMR resonance assignments
1H chemical shifts and resonance assignments were estab-
lished using two-dimensional 1H-1H TOCSY (total correlation
spectroscopy) and nuclear Overhauser eﬀect spectroscopy
(NOESY) experiments [33] and are reported in Tables 1 and
2. Interestingly, in the presence of antibody, a slight low-fre-
quency (shielded) shift of the amide protons was observed
for residues His24 and Trp25; however, observation of an
opposite shift, high-frequency (unshielded) shifted HN reso-
nance particularly for Asp32, pSer33, Gly34 and pSer37 may
be an indicator of intermolecular contact of the phosphory-
lated motif with the binding site. The unshielding eﬀect ob-
served for the negatively charged fragment D32-T42 could
reﬂect the positive charged contact of the antibody surface.
Hence the binding region encompasses the immunogene
diphosphorylated peptide 32–45 region. A low shielding eﬀect
in the upstream hydrophobic region could also indicate an
additional contribution in the interaction of P-b-Cat19–44
peptide with mAb BC-22.Table 2
1H NMR chemical shifts (ppm) of the P-b-Cat19–44 peptide bound to antibo
Residue d NH d Ha d Hb
Ac
Lys 19 8.42 4.25 1.81
Ala 20 8.52 4.29 1.39
Ala 21 8.46 4.32 1.39
Val 22 8.27 4.12 2.05
Ser 23 8.52 4.42 3.80/3.74
His 24 8.58 4.63 3.09
Trp 25 8.15 4.57 3.25
Gln 26 8.14 4.11 1.96/1.79
Gln 27 8.26 4.12 2.05/1.99
Gln 28 8.53 4.29 2.01/1.96
Ser 29 8.44 4.42 3.80
Tyr 30 8.30 4.57 2.96/3.04
Leu 31 8.21 4.32 1.55
Asp 32 8.22 4.61 2.75
pSer 33 9.26 4.45 4.18/4.12
Gly 34 8.63 3.93
Ile 35 8.07 4.04 1.80
His 36 8.79 4.81 3.16/3.32
pSer 37 9.40 4.46 4.10
Gly 38 8.77 4.02
Ala 39 8.29 4.42 1.45
Thr 40 8.45 4.45 4.27
Thr 41 8.39 4.46 4.26
Thr 42 8.36 4.33 4.17
Ala 43 8.57 4.61 1.38
Pro 44 4.39 2.32/1.96
NH2
aSpectra were recorded at 278 K and pH 7.2 with a 100:1 P-b-Cat:mAb ratio
volume).2.3. Interaction of P-b-Cat19–44 with mAb BC-22
The dissociation constant was estimated from the line broad-
ening at diﬀerent peptide:antibody ratios to be 200 lM
[29]. These measurements show that the phosphorylated
DpSGIHpS motif is necessary for binding, but residues from
the longer peptide P-b-Cat19–44 do contribute additional bind-
ing energy. Because of the low mAb:peptide molar ratio, free
and bound peptide molecules were in rapid chemical exchange
and only a single set of broadened ligand resonances was ob-
served. To provide additional information regarding the pep-
tide mode of binding, STD NMR experiments (Fig. 2) were
performed [30–32]. The STD NMR technique is a method
which could give an epitope mapping by NMR spectroscopy.
Resonances of the protein are selectively saturated, and in a
binding ligand, enhancements are observed in the diﬀerence
(STD NMR) spectrum resulting from subtraction of this spec-
trum from a reference spectrum in which the protein is not sat-
urated (Fig. 2) [30–32]. Protons of the ligand which are in close
contact with the protein can be identiﬁed from the STD NMR
spectrum, because they are expected to be saturated to the
highest degree. The individual signal protons of the P-b-
Cat19–44 peptide are best analyzed from the intensity values
than the integral values in the reference (I0) and STD spectra
(ISTD = I0  Isat). The spectral region corresponding to the
amino protons is well resolved and can be used to classify
the amino acid residues relevant for interaction with the anti-
body. The moderate degree of overlapping for the amide pro-
tons allowed us to calculate the intensity for all the visible
amide protons of the peptide. The signals observed in the 1D
spectra for the amide protons of the whole peptide are summa-
rized in Fig. 2.dy mAb from TSP-d4
a
d Hc d Hd d others
2.03
1.46 1.71 3.00
0.93/0.89
2H 8.16; 4H 7.10
NeH 10.24 2H 7.24; 4H 7.54; 5H 7.15; 6H 7.25; 7H 7.49
2.11 6.93/7.51
2.35 7.01/7.66
2.31 6.96/7.60
7.09 6.81
1.45 0.83/0.89
Hc1 1.19/1.44 Hc2 0.82 0.82
2H 8.10; 4H 7.23
1.24
1.22
1.23
2.07/2.03 3.68/3.82
7.79/7.15
, and 20 mM sodium phosphate buﬀer in a 9:1 H2O/
2H2O mixture (by
Fig. 2. Epitope mapping of the P-b-Cat19–44 peptide in the presence of mAb, for a peptide:antibody ratio of 100:1. Expansion of the region
containing resonances of the amide protons: Reference 1D 1H spectrum (in black) of the P-b-Cat19–44 peptide in association with the mAb antibody
and 1D 1H STD NMR spectrum (in red) of the P-b-Cat19–44 peptide in association with the mAb antibody, showing enhancements of resonances of
protons making close contacts with the antibody-combining site. STD values are obtained after peak picking intensities compared to the 1D with the
exact values of chemical shifts of the HN (in bold: amino acids with intense relative STD, and in italic: amino acids with weak relative STD).
Variations of the chemical shifts between the HN are equal to or higher than 0.01 ppm. There are only Ala20 and Ser23, which pose problem since
they leave together to 8.52 ppm. The value given can thus correspond only to the average of relative STD value found for each one.
Fig. 4. TRNOE build-up rates of P-b-Cat19–44 peptide with or without
mAb vs. mixing time (ms). The ligand to antibody ratio is 100:1. The
curves represent the intra-residue connectivity HN/Ha of His36 and
pSer37.
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pSer33 and Asp32 H–N proton, was normalized to 100%
(Fig. 3). The relative degree of saturation for the individual
protons, normalized to that of pSer33 or Asp32, can be used
to compare the STD eﬀect [32]. For reference, the STD
NMR spectrum was recorded with a sample containing the
nonphosphorylated b-Cat19–44 peptide, and all signals from
nonbinding peptide were completely eliminated.
Fig. 2 shows the 1D STD NMR spectrum and a normal 1H-
spectrum of the complex of P-b-Cat19–44 with the antibody.
The pSer33 (99%) and Asp32 (100%) H–N resonances, and
other pSGIHpS motif resonances belonging to either Gly34
(85%), Ile35 (74%), His36 (61%) or pSer37 (52%), have similar
STD intensities between 50% and 100% (Fig. 4). Obviously,
these residues have more and tighter contacts with the anti-
body’s surface. On the other hand, side chains resonances
and H-N resonances of Trp25 (79%), Gln26 (70%) andFig. 3. Relative STD intensities (in percent) of the amide protons of
the individual amino acids calculated for each amino acid of the P-b-
Cat19–44 peptide from the 1D spectrum.Gln27 (52%) have similar larger STD intensities, ranging from
50% to 80%, indicating that these side chains are involved in
the epitope. The lowest intensities are found for the protons
of the N-terminal group, residues K19-A21 and the C-terminal
group, residues T40-A43, which reach values of only 10–20%.
Proton signals of the acetyl group at 2.03 ppm and of the
amide group at 7.79 ppm and 7.15 ppm strongly decreased or
disappeared completely in the STD spectra indicating that
the terminal group are not involved in the interaction. Thus,
a clear distinction between protons with a strong contact to
the protein and the others can be made.
The combination of STD NMR epitope mapping data with
knowledge of the bound conformation of the ligand, which
may be obtained by TRNOESY experiments, is a powerful
method for building up models of antibody–ligand interaction
[34,35].
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Cat19–44 peptide
The bound conformation of the peptide was investigated by
TRNOESY experiments [36]. According to the TRNOE build-
up curves [37] of P-b-Cat19–44 peptide, the mixing time of the
transferred NOE experiment was set to 200 ms. The observa-
tion of TRNOE cross-peaks, when mAb was added, attested
to peptide-antibody interaction and the restricted ﬂexibility
of the mAb-bound peptide. We observed faster rate of build
up for the peptide in presence of mAb (Fig. 4), which indicated
the binding of the peptide to the mAb. The observation of sup-
plementary TRNOE cross-peaks (Fig. 5), when the antibody
was added, attested the peptide–protein interaction. Signiﬁcant
diﬀerences were observed between the NOESY spectra of the
free peptide and the one of the petide bound to the antibody,
indicating that the cross-peaks observed in presence of anti-
body are in fact TRNOEs (Figure S1 in Supporting Informa-
tion). For instance, there is 12 new daN(i, i + 2) observable
connectivities (between residues 19–21, 20–22, 21–23, 23–25,
24–26, 26–28, 27–29, 28–30, 35–37, 37–39, 39–41 and 40–42)
for the bound peptide. In a similar manner, four daN(i, i + 3)
appeared in the N-terminal part of the bound peptide (21–
24, 22–25, 25–28 and 26–29), and two dab(i, i + 3) were newly
present on each side of the DpS33GIHpS37 motif (30–33 and
37–40). The daN(i, i + 4) are also numerous only in the bound
peptide and essentially in the N-terminal part (19–23, 21–25,
23–27, 24–28, 25–29, 26–30, 27–31 and 35–39, 39–43).
A summary of sequential d(i, i + 1) and medium-range
d(i, i + 2) and d(i, i + 3) 1H–1H NOE connectivities is presented
in Fig. 5. The large number of TRNOESY connectivities
involving side chain protons of the aromatic residues (His24,
Trp25, Tyr30, and His36) as well as the side chain protons
of many residues and the main backbone appeared upon addi-
tion of the antibody (for instance, between 2H of Trp25 and
2H of His24, or between 2H of His36 and Ha of Gly38) sug-
gests that the aromatic side chains rings are rather frozen in
the bound state.
The TRNOE spectrum exhibits a great number of NOEs,
including intense and medium NN(i, i + 1) connectivities
(Fig. 5), suggesting secondary structures (helix, turn, bend,
or strand). The aN(i, i + 2), aN(D32-G34, pS33-I35, I35-
pS37) peaks argue in favor of a folded structure for the
DpS33GIHpS37 sequence which includes the pSer phosphory-
lated site. In this motif, where a bend was apparent, the fourFig. 5. Sequential d(i, i + 1), and medium range d(i, i + 2), and d(i,
i + 3) 1H-1H TRNOE connectivities in the P-b-Cat19–44 peptide
(sequence at the top) in the presence of the mAb antibody at 278 K
and pH 7.2. The thickness of the lines reﬂects the relative intensities of
the NOEs within the individual plots.aN(i, i + 2) and the two ab(i, i + 3) ab(Y30-pS33 and H36-
A39) connectivities helped to deﬁne this bend. The aN(i,
i + 3), and ab(i, i + 3) connectivities attests that the phosphor-
ylated peptide adopts a well-deﬁned and folded structure in the
presence of the antibody. In particular, residues 20–32 have
NOE connectivities that suggest the presence of a turn or
half-turn structure. The seven aN(i, i + 3) connectivities are
diagnostic of a propensity for a turn region located just before
the DpS33GIHpS37G motif.
To study the conformation of the bound state of P-b-
Cat19–44 in the presence of the mAb antibody the distance re-
straints were incorporated into a simulated annealing protocol
using ambiguous restraints for iterative assignment (ARIA)
[38,39]. A set of 20 structures produced by simulated annealing
was subjected to energy minimization, followed by checks for
correct geometry and agreement with the distance restraints
(Fig. 6). The structural models ﬁt the NMR data well, with
no violations of experimental distance restraints greater than
0.3–0.5 A˚. The positions of the backbone and most side chain
atoms were well deﬁned by the NMR restraints. Structural sta-
tistics are presented in Table 3.
The average root-mean-square diﬀerence for superimposi-
tion of the 10 structures with the lowest NOE restraint energy
was 2.1 A˚ for the backbone atoms (N, Ca, C, and O) of resi-
dues 19–37. Lower root-mean-square deviation (rmsd) was ob-
tained when the superposition was carried out separately for
the central segment 25–36 (1.4 A˚) and the partially-helical re-
gion at the N-terminal segment 19–25 (1.5 A˚). This is con-Fig. 6. NMR TRNOE-derived structures of the bound peptide P-b-
Cat19–44 peptide in the presence of the mAb antibody. (A) Twenty
structures of P-b-Cat19–44 were generated after eight iterations with
ARIA software. The best ﬁve are displayed. The molecules are ﬁtted
from residue 25 to residue 36. (B) The minimum energy-minimized
conformer with the best ﬁt of proton distance constraints.
Table 3
Structural statistics of the ﬁnal 10 NMR structures of P-b-Cat19–44
bound to the mAb antibody
No. of experimental distance restraints
Unambiguous NOE 311
Ambiguous NOE 92
Total NOEs 403a
No. of experimental broad dihedral restraints 23
NOE violations >0.3 A˚ per structure 1.5
Rms diﬀerences from mean structureb (A˚)
Backbone (residues 19–25) 1.5 ± 0.4
Heavy (residues 19–25) 2.6 ± 0.6
Backbone (residues 25–36) 1.4 ± 0.4
Heavy (residues 25–36) 2.8 ± 0.6
Ramachandran plot of residuesc (%)
In most favored regions 57.7
In additional allowed regions 39.6
In generously allowed regions 2.3
In disallowed regions 0.4
aNOEs: 194 intra-residue, 98 sequential, 98 medium-range and 13
long-range.
bCalculated with MOLMOL.
cCalculated with PROCHECK NMR.
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residue of the bound structure of P-b-Cat19–44. The increased
or decreased ﬂexibility of the segments may be appreciated
from the magnitude of the local rmsd which highlights a higher
stability of residues 20–31 (local rmsd values around 0.1 A˚).
The values are slightly higher for residues D32-pS33 (in the
range of 0.4–0.5 A˚), and drop signiﬁcantly until 0.7–0.8 A˚
for residues G34-H36 and T41-A43. There is more disorder
in the terminal parts of the peptide, which are less well deﬁned
by the TRNOEs. This is consistent with the total number of
NOE constraints observed per residue. Interestingly, the
well-ordered part of the peptide corresponds to the residues
22–37, which were the most involved in the binding with the
antibody, a hypothesis consistent with the STD NMR data.Fig. 7. (A) The minimum energy conformer of the free P-b-Cat17–48
which contains phosphoserines pSer33 and pSer37. The surface
representation is colored according to the electrostatic potential (red
for the negative region and blue for the positive surface). (B)
Superimposition of the mAb P-b-Cat19–44 bound peptide (in blue),
and the P-b-Cat17–48 free peptide (in yellow) and superimposition of
the 32DpSGXXpS37 fragment.3. Discussion
3.1. Conformation of P-b-Cat19–44 Bound to mAb
The ensemble of ﬁve lowest energy structures is shown in
Fig. 6A. The structures are ﬁtted from residues 25 to 36. The
bound conformation of the peptide showed a propensity for
turn formation in N-terminal residues, and a bend including
the DpS33GIHpS37G phosphorylation motif (Fig. 6B). When
bound to the mAb, the phosphorylated peptide adopts a
folded structure, which reﬂects the local rearrangement of
the DpSGXXpS phosphorylation site at the interface with
the mAb. The conformation of the mAb-bound P-b-Cat19–44
peptide is signiﬁcantly represented in the free phosphorylated
peptide (Fig. 7). Interestingly, the main structural changes
are observed in the motif region of the P-b-Cat19–44 peptide,
which is modiﬁed upon binding as reﬂected by a diﬀerent ori-
entation of the phosphorylated residue pSer37. Hence, in the
free P-b-Cat17–48 peptide structure, the phosphate groups have
a nearly coplanar orientation while in the bound structure they
have an opposite coplanar orientation (Fig. 7B).
The bend is similarly found in the mAb and also in the b-
TrCP-bound P-b-Cat17–48 peptide [28], as shown in Fig. 8.To elucidate the basis of b-TrCP recognition, the structure
of the P-b-Cat17–48 peptide bound to the F-Box Protein b-
TrCP was previously determined by NMR and molecular
dynamics [28]; the residues 30–37 formed a bend while the
phosphate groups point away. The b-turn motif also plays a
central role in the crystal structure of the human b-TrCP1-
Skp1 complex bound to a fragment b-catenin peptide [40]
(Fig. 9A and B). In the crystal structure, only an 11 residue
segment (residues 30–40) of the b-Catenin, centered on the
doubly phosphorylated motif (DpS33GXXpS37), makes the
largest number of contacts with b-TrCP1 (Fig. 9B). The phos-
phoserine, aspartic acid, and hydrophobic residues of the motif
makes direct contacts with b-TrCP1. Interaction of b-Catenin
with the P-b-Cat speciﬁc monoclonal antibody relies on the
DpSGXXpS motif, similar to that found in the other
substrates of b-TrCP (IjBa and HIV-1 Vpu). The turn
conformation is often important in allowing peptide side
Fig. 8. (A) Superimposition of the mAb-P-b-Cat19–44 bound peptide (in blue), and the b-TrCP-P-b-Cat17–48 bound peptide (in grey) [28]. The two
structures are ﬁtted from residue 33 to 36. (B) Superimposition of the 32DpSGXXpS37 fragment of the mAb P-b-Cat19–44 bound peptide (in blue), and
the b-TrCP-P-b-Cat17–48 bound peptide (in grey) [28].
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make speciﬁc contacts with residues within the site. This is
clearly important here as is shown by the epitope mapping
data where (H24-W25) and (D32-S37) side chains contact
the site.
3.2. The epitope mapping of the bound P-b-Cat19–44 with mAb
The STD ampliﬁcation factors of the amide protons were
classiﬁed (Fig. 3). Nearly all the NH of the DpSGXXpS motif
interact strongly with the corresponding amino acids inside the
paratope. In the bound structures of P-b-Cat19–44 peptide, the
DpSGXXpS motif and N-terminal part are well-deﬁned re-
gions characterized by a low local rmsd and these regions
are involved in the binding surface contact of b-Catenin with
the mAb protein.
The DpS33GXXpS37 bend form a negatively charged surface
(in red, Fig. 7A) that would provide a plausible binding region
similar to the negative b-Catenin substrate peptide in contact
with the positive protein b-TrCP surface shown in Fig. 9A.
The position of DpSGXXpS within a larger, extended epitope
may be designed to present the phosphate group to antibodies.
The phosphate group of pSer33 is able to make the largest
number of contacts making electrostatic interactions and
hydrogen bonds. Asp32, which is an invariant binding motif
residue, is also able to make an extensive contact as its side
chain allows hydrogen bonding with some residues of mAb
BC-22. Gly34, also an invariant binding motif residue, is able
to pack with the antibody receptor in an environment with lit-
tle space for a nonglycine residue.
Hence, we made the superimposition from residue 33 to 36
of the lowest energy structure of the bound peptides with
mAb and b-TrCP (Fig. 8B), and the recent crystal structure(Fig. 9C). A good agreement is found between the three struc-
tures, essentially for the DpSGX region of the consensus
DpSGXXpS motif. The side chain of the ﬁrst phosphoserine
pSer33 points in the same direction and the phosphate groups
are found close together. However, in the consensus
DpSGXXpS motif, the XpS region containing the second
phosphoserine is found to be very diﬀerent which involved a
large distance between the phosphate groups of pSer37 in the
three structures. Interestingly, this result highlighted the strong
implication that the ﬁrst phosphoserine pSer33 of b-catenin
should have with mAb and b-TrCP (Figs. 9B and C), while
the phosphate group of pSer37 could interact with many pos-
itively charged amino acids. Thus, the main diﬀerence ob-
served between all the known bound structures of peptides
interacting with mAb or b-TrCP resides in diﬀerent positions
of the phosphorylated residue pSer37 (Figs. 9B and C). An
excellent agreement is found between the amide protons with
the strongest relative STD intensities and the corresponding
residues in the crystal structure. Thus, either by using STD
NMR experiments or by inspection of the crystal structure,
the DSG motif was found to make the closest contacts with
mAb or b-TrCP.
The region after the DSGXXS motif is less important for
binding. As evidenced by STD experiments, the C-terminal
A39-G48 region of P-b-Cat19–44 peptide is less implicated with
mAb. In addition, the C-terminal region (starting from Ala39)
appeared with less numerous NOEs constrains and a higher lo-
cal rmsd. On the other hand, the NH of the Trp25 and His36
aromatic residues are recognized as evidenced by STD NMR
experiments. Aromatic protons which classically possessed lar-
ger T1 relaxation times relative to other protons found in pep-
tides or proteins could be overestimated in STD experiments
Fig. 9. (A) Surface representation of the top face of the b-TrCP WD40
domain with the bound DpSGXXpS motif from the crystal structure
of the human b-TrCP-SkP1 complex bound to a b-Catenin substrate
peptide [40]. The surface is colored according to the electrostatic
potential (red for the negative region and blue for thee positive
surface).
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times of T1 (the average value for T1 was around 500 ms), sig-
nals of Trp25 and essentially those coming from the aromatic
chain were always the stronger ones observed in STD experi-
ment. Tryptophan is a rarely found aromatic residue (1.2%)
and its position upstream of the DSG motif could reﬂect the
particular role of tryptophan as that had been observed in
the study of the interaction of b-Catenin with b-TrCP [28].
His24 and Trp25 whose hydrophobic nature is conserved in
the peptide fragment (in white, Fig. 7A) are able to make
hydrophobic and/or p–p interactions with a hydrophobic
pocket in mAb. The antibody was developed against a syn-
thetic peptide (32DpS GIHpSGATTTAPS45), however the
NMR studies performed with mAb and P-b-Cat19–44 show that
a region of sequence upstream of the DSG motif that was not
included in the antigenic peptide directly contacts mAb. These
contacts could be assigned as non-speciﬁc. However, residues
His24 and Trp25 are in close proximity to the DSG motif
and they could participate to increase indirectly the aﬃnity
of the binding region.
Finally, the NMR data described above show that the epi-
tope comprises a surface extending over residues of the
DpSGXXpSmotif, with contributions being made by the main
chain of hydrophobic residues His24 and Trp25. These obser-
vations are consistent with the sequence requirements playing
a role in interaction with the b-TrCP protein, the bend
DpSGXXpS motif of the bound P-b-Cat19–44 peptide associ-
ated with the hydrophobic and/or p–p cluster (H24-W25).
The reﬁned conformation of the P-b-Cat19–44 peptide in the
binding sites of its monoclonal antibody is necessary to under-
stand the biological action of the overall b-Catenin protein
phosphorylated at sites pSer33 and pSer37. The data presented
here are important for reﬁning the bound phosphorylated
structures and provide valuable assistance in the interpretation
of the NMR investigation of the complexes of these peptides
linked to their binding proteins. Taken together, our data
are consistent with the idea that the speciﬁc monoclonal anti-
body and b-TrCP interactions with the phosphorylated pep-
tide are to a great extent analogous. The similarities
observed in the P-b-Cat17–48 peptide (including the phosphor-
ylation motif DpS33GXXpS37) while bound to b-TrCP in con-
junction with highly reﬁned structures free in solution and in
the antibody-bound states, will facilitate understanding of
the basic mechanisms involved in b-TrCP-receptor interactions
and proteasome targeting of the oncogenic protein b-Catenin.4. Materials and methods
4.1. Peptides
b-Catenin (b-Cat) fragments (residues 19–44), the P-b-Cat19–44 (and
b-Cat19–44) peptides containing phosphorylated sites 33 and 37 with
the Ac-K19AAVSHWQQQSYLDpSGIHpSGATTTAP44-NH2 amino
acid sequence, were synthesized in the group of Francoise Baleux, Pas-
teur Institute (Paris, France). The purity of the peptides (90%) was
tested by analytical HPLC and by mass spectrometry.Fig. 9 (B) Close-up view of the DpSGXXpS motif, from the crystal
structure and recognized by the F-box protein b-TrCP [40]. (C)
Superimposition of the 32DpSGXXpS37 fragment of the mAb P-b-
Cat19–44 bound peptide (in blue), the b-TrCP-P-b-Cat17–48 bound
peptide (in grey) [28] and the crystal structure (in green) [40].
b
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Monoclonal anti-diphospho P-b-Cat (pSer33 and pSer37) was pur-
chased from Sigma–Aldrich (Ref. C4231, clone BC-22, referred to as
mAb antibody). This antibody (mouse IgG2b isotype) was developed
against a synthetic peptide (32DpS GIHpSGATTTAPS45) correspond-
ing to amino acids 32–45 (pSer33 and pSer37) of Human b-Catenin
conjugated to KLH (Keyhole Limpet Hemocyanin). Nonphosphory-
lated or monophosphorylated (Ser33) peptides were used as a negative
control. The antibody concentration was estimated to be 2 mg/mL
with an approximate molecular mass of 160 kDa, in a solution
20 mM phosphate buﬀered saline (pH 7.4), containing 15 mM sodium
azide. This amount of puriﬁed antibody was used to prepare the NMR
samples.
4.3. NMR experiments
1H NMR spectra were recorded at 278 K on a Bruker Avance-500
spectrometer using a z-axis gradient. Chemical shifts assignments (Ta-
bles 1 and 2) refer to internal 3-(trimethylsilyl)propionic acid-2,2,3,3-d4
sodium salt (TSP-d4). Two-dimensional NMR spectra were recorded in
the phase-sensitive mode using the States-time-proportional phase
incrementation method [42]. All experiments were carried out using
the 3-9-19 binomial water suppression by gradient-tailored excitation
pulse sequence for water suppression [43]. Two-dimensional 1H–1H
TOCSY spectra were recorded using a MLEV-17 spin-lock sequence
[44] with a mixing time of 70 ms. Typically, spectra were acquired with
256 t1 increments, 2048 data points, and a relaxation delay of 1.5 s.
Spectra were processed using XWIN NMR software. All spectra were
zero-ﬁlled in the F1 spectral dimension to 1024 data points followed by
forward linear prediction of 512 points. Finally, a square cosine bell
window function was applied in both dimensions prior to Fourier
transformation. For preparation of NMR peptide-antibody samples,
the antibody solution (200 ll) was diluted in NMR phosphate buﬀer
(20 mM phosphate, 5% D2O, and 0.02% NaN3) at pH 7.2. The ﬁnal
sample (250 ll in a Shigemi tube) contained 0.4 mg of antibody
(0.01 mM) and 1 mM peptide, leading to a ligand:antibody ratio of
100:1.
For STD experiments (Fig. 2), the one-dimensional (1D) 1H STD
NMR [31,32,45] spectra of the mAb-peptide complex (Fig. 2A) were
recorded at 500 MHz with 2048 scans and selective saturation of pro-
tein resonances at 12 ppm or 3 ppm (30 ppm for reference spectra)
showing that by irradiating at 3 ppm, the antibody can be saturated
uniformly and can therefore be eﬃciently used for the STD NMR tech-
nique. Investigation of the time dependence of the saturation transfer
with saturation times from 0.2 to 4.0 s showed that 2 s was needed for
eﬃcient transfer of saturation from the protein to the ligand protons.
STD NMR spectra were acquired using a series of 40 equally spaced
50 ms Gaussian-shaped pulses for selective saturation (then, a total
saturation time was of approximately 2 s) [46], with 1 ms delay between
the pulses. With an attenuation of 50 dB, the radiofrequency ﬁeld
strength for the selective saturation pulses in all STD NMR experi-
ments was 186 Hz. Subtraction of FID values with on- and oﬀ-reso-
nance protein saturation was achieved by phase cycling.
Transferred nuclear Overhauser eﬀect (TRNOESY) [36] spectra of
the mAb-peptide complex were recorded with 4 K points and 512 t1
increments, and a relaxation delay of 1 s. Data processing were per-
formed by zero ﬁlling to 1 K points in F1 to give a ﬁnal 4 K · 1 K ma-
trix. The bound and free states exist in the same regime, namely
xsc > 1; thus, the cross-relaxation rates of the P-b-Cat
19–44 peptide
(MW = 2943 g/mol) in the free and bound state are negative in sign.
The optimal conditions for the TRNOESY measurements were deter-
mined by considering a peptide:mAb molar ratio ranging from 100 to
200 with mixing times (sm) of 50, 100, 200, 400 and 600 ms. The build-
up curve [37] for diﬀerent NOE correlations showed that spin diﬀusion
was negligible for a sm of 200 ms (Fig. 4). The faster rate of build-up
for the pairs (intra-residue HN/Ha NOEs for His36 and pSer37) in
the bound state vs the free state, as shown in Fig. 4, indicated that
the eﬀects are representative of the bound state. The observed TRNOE
correlations with mixing times of 100 and 200 ms were intense and neg-
ative. They were assigned to the mAb-bound antigen [47] as a sample
of the peptide without the presence of antibody exhibited only intra-
residue and sequential NOE intensities with a mixing time of 200 ms.
Automatic baseline correction was performed prior to integration of
cross-peak volumes using FELIX (Accelrys). Cross-peaks intensities
were converted to interproton distances using the distance between
the two Tyr-aromatic protons (2.42 A˚) as a reference. TRNOE cross-peaks classiﬁed as strong, medium, weak and very weak were con-
verted into distance restraints of 1.8–2.7, 1.8–3.6, 1.8–5.0 and 1.8–
6.0 A˚, respectively.
4.4. Structure calculations
Distance restraints used in the structure calculations were derived
from TRNOESY experiments performed with mixing time of
200 ms. The ﬁnal list of distant restraints containing 311 unambiguous
and 92 ambiguous restraints (194 intra-residue, 98 sequential, 98 med-
ium-range and 13 long-range) (Table 3) was incorporated for structure
calculation with the standard protocol of ARIA 1.2 [38,39]. Modiﬁca-
tions of the phosphorylated residues (pSer) were introduced with
CHARMM [48] for molecular dynamics calculations using the PAR-
ALLHDG 5.3 force ﬁeld. During the calculations, non-glycine residues
were restrained to negative / values (usually the only range considered
in NMR-derived structures) [49]. The simulated annealing protocol
consisted of four stages: a high-temperature torsion angle simulated
annealing phase at 10000 K (30 ps), a ﬁrst torsion angle dynamics
cooling phase from 10000 K to 50 K (15 ps), a second Cartesian
dynamics cooling phase from 2000 K to 50 K (27 ps), and a ﬁnal min-
imization phase at 50 K. ARIA enabled the incorporation of ambigu-
ous distance restraints and calibration of the NOE restraints using
automated matrix analysis as implemented by the program. ARIA
runs were performed using the default parameters with eight iterations.
Twenty structures were generated each round, and the 10 lowest-en-
ergy structures were carried on to the next iteration. In the ﬁnal itera-
tion, the 20 lowest-energy structures were retained as the ﬁnal
structures. Even if ARIA is able to generate structures of the free pep-
tide with a ﬁnal energy minimization step in a simulated water box, it
was decided that due to the presence of the bound peptide in the
hydrophobic antibody recognition sites this step was not applicable.
The set of P-b-Cat19–44 structures was selected for correct geometry
and no distances restraint violations of >0.5 A˚. Analysis of the struc-
tures was performed within Aqua, PROCHECK NMR [50] programs
(Table 3). MOLMOL [51] was used for the analysis and presentation
of the results of the structure determination.5. Notes
The coordinates were deposited in the Protein data Bank
with the following code: 2G57. The chemical shift assignment
Tables were deposited in the Biomagnetic Resonance Data
Bank with the BMRB accession number: 7001.
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Figures TRNOESY spectrum of the P-b-Cat19–44 peptide in
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